Table 3.
Association of lipid-lowering treatment with recurrent VT among the full cohort and by CVD status
| Non-users of statins |
Recent stoppers of statins |
Current users of statins | ||||
|---|---|---|---|---|---|---|
| Any statin | Simvastatin | Lovastatin | Other statin | |||
| Full Cohort | ||||||
| Person-years | 5967.3 | 561.9 | 2844.1 | 1671.5 | 750.4 | 422.1 |
| Events | 313 | 32 | 112 | 62 | 34 | 16 |
| Rate/100-PYs | 5.2 (4.7–5.9) | 5.7 (4.0–8.1) | 3.9 (3.3–4.7) | 3.7 (2.9–4.8) | 4.5 (3.2–6.3) | 3.8 (2.3–6.2) |
| Adjusted HR*(95% CI) | 1.0 (reference) | 0.89 (0.61–1.3) | 0.74 (0.59–0.94) | 0.76 (0.57–1.0) | 0.71 (0.49–1.0) | 0.79 (0.47–1.3) |
| P-value | - | 0.540 | 0.013 | 0.055 | 0.063 | 0.367 |
| Cohort without Prior CVD | ||||||
| Person-years | 5305.3 | 318.2 | 1449.3 | 930.3 | 378.7 | 140.3 |
| Events | 282 | 19 | 49 | 30 | 14 | 5 |
| Rate/100-pys | 5.3 (4.7–6.0) | 6.0 (3.8–9.4) | 3.4 (2.6–4.5) | 3.2 (2.3–4.6) | 3.7 (2.2–6.2) | 3.6 (1.5–8.6) |
| Adjusted HR* (95% CI) | 1.0 (reference) | 1.00 (0.62–1.6) | 0.62 (0.45–0.85) | 0.62 (0.42–0.92) | 0.55 (0.32–0.94) | 0.92 (0.38–2.2) |
| P-value | - | 0.990 | 0.003 | 0.017 | 0.031 | 0.851 |
| Cohort with Prior CVD | ||||||
| Person-years | 660.4 | 247.5 | 1392.5 | - | - | - |
| Events | 31 | 13 | 63 | - | - | - |
| Rate/100-pys | 4.7 (3.3–6.7) | 5.3 (3.0–9.0) | 4.5 (3.5–5.8) | - | - | - |
| Adjusted HR* (95% CI) | 1.00 (reference) | 0.99 (0.52–2.0) | 1.1 (0.70–1.7) | - | - | - |
| P-value | - | 0.966 | 0.704 | - | - | - |
CVD = Cardiovascular disease; PY = person years; HR = hazard ratio; CI = confidence interval.
*
Adjusted for age, sex, race, BMI, idiopathic incident event, and time-dependent cancers, smoking status, CVD, anticoagulation therapy, aspirin use, hospitalization, and fracture.